General Information of Drug (ID: DM8OYI4)

Drug Name
Platinum IV complexe 1 Drug Info
Synonyms PMID26394986-Compound-69
Cross-matching ID
TTD Drug ID
DM8OYI4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID26394986-Compound-10 DMP8RQ4 N. A. N. A. Patented [1]
PMID26394986-Compound-56 DMPNJ4X N. A. N. A. Patented [1]
Indirubin derivative 1 DMB8673 N. A. N. A. Patented [1]
PMID26394986-Compound-57 DMILUT8 N. A. N. A. Patented [1]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acitretin DM8BKU9 Psoriasis vulgaris EA90 Approved [2]
Napabucasin DMDZ6Q3 Colorectal cancer 2B91.Z Phase 3 [3]
Golotimod DMKZN3A Immune System disease 4A01-4B41 Phase 2 [4]
NT219 DMOYS1N Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
WP-1066 DMUGHWR Recurrent glioblastoma 2A00.00 Phase 1/2 [3]
Atiprimod DM84YEC Multiple myeloma 2A83 Phase 1/2 [6]
OPB-31121 DM6VGO3 Hepatocellular carcinoma 2C12.02 Phase 1/2 [7]
IMX-110 DMNHZS4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
GLG-801 DMY1CP9 Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [3]
OPB-51602 DM760FA Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID26394986-Compound-10 DMP8RQ4 N. A. N. A. Patented [1]
Oxazole derivative 1 DM7Y2RL N. A. N. A. Patented [1]
Peptidomimetic analog 5 DMF0DE2 N. A. N. A. Patented [1]
Peptide analog 8 DMFG7A8 N. A. N. A. Patented [1]
AVT-02 UE DM8NA4M Skin infection 1F28-1G0Z Discontinued in Phase 2 [9]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Signal transducer and activator of transcription 1 (STAT1) TTN7R6K STAT1_HUMAN Inhibitor [1]
Signal transducer and activator of transcription 3 (STAT3) TTH8FZW STAT3_HUMAN Inhibitor [1]
Signal transducer and activator of transcription 5 (STAT5) TTLRFIH STA5A_HUMAN; STA5B_HUMAN Inhibitor [1]

References

1 A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
2 Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 National Cancer Institute Drug Dictionary (drug id 617379).
5 Clinical pipeline report, company report or official report of Purple Biotech.
6 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
7 OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52.
8 Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005.
9 Avontec Announces Results of a Multiple Dose Clinical Phase I Study with Its Drug Candidate AVT-02 UE Ointment After Topical Treatment in Male Healthy Volunteers. Avontec. 2008.